Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis

NCT06374459 PHASE1, PHASE2 RECRUITING

This is a phase Ib/II study evaluating the safety and efficacy of zunsemetinib (ATI-450) with capecitabine in patients with hormone receptor-positive and HER2-negative (HR+/HER2-) metastatic breast cancer (MBC).

Details

Lead sponsor	Washington University School of Medicine
Phase	PHASE1, PHASE2
Status	RECRUITING
Enrolment	152
Start date	Thu Jan 30 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Mon May 31 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer

Interventions

• Zumsemetinib
• Capecitabine
• Zoledronic acid
• Denosumab

Countries

United States